I enjoyed two full months of recovery from the latest attempt to control my cancer, multiple myeloma. At first, that drug worked well. The harsh side effects, however, made me […]
I was tempted to entitle this blog ‘My Life Lived in Fear’, but after some reflection, I decided that some could perceive that to be melodramatic. That said, I am prone to a dash of daily sensationalism, so I couldn’t not tell you. The blog’s working title concisely and accurately summarises this current stage of […]
The post I had intended to write around the 7 months post transplant mark was going to be a slightly celebratory post about being able to enjoy “dirty” food having adhered to a clean diet for the first 6 months … Continue reading →
Ask the Expert: The type of cancer, patient’s age, general health, availability of donors and other factors determine the type of transplant
Is one person’s bone marrow literally transplanted into another during a bone marrow transplant?
Hematopoietic stem cell transplants (commonly referred to as bone marrow transplants) are typically used to treat blood cancers such as leukemia, lymphoma and multiple myeloma.
Hematopoietic stem cell transplant encompasses peripheral blood stem cell transplant, bone marrow transplant and alternative donor transplant as well. In the majority of cases, the source of the stem cell to complete the transplant is taken from the bloodstream of the patient or a donor (peripheral blood stem cell transplant).
In a smaller number of cases, the patient may receive stem cells from umbilical cord blood or stem cells from a donor’s actual bone marrow.
If the stem cells are taken from the patient, it is called an autologous transplant. If the stem cells are from a donor, it is an allogeneic transplant. Both types of transplants use hematopoietic stem cells that can have the capacity for self-renewal and the ability to form all types of blood cells including red blood cells, white blood cells and platelets.
The stem cells are transfused into the patient’s bloodstream, where they migrate to the bone marrow and grow into healthy new blood cells and therefore repopulate the bone marrow.
In autologous transplants, the dose of chemotherapy is what provides the benefit of disease control/cure. It is more commonly considered as a therapeutic modality for multiple myeloma, where it offers disease control and for recurrent Non-Hodgkin Lymphoma or Hodgkin’s disease where it has the potential for cure.
In allogeneic transplants, the dose of chemotherapy provide benefit but also the interaction between the donor and recipient cells allow a protective response called graft versus tumor effect. It should be noted that each type of transplant is associated with its own risks and benefits.
If an allogeneic transplant is to be performed, a donor search is initiated. Donors have to be closely genetically matched. The donor search usually begins with full blood siblings, who have about a 25 percent chance of being a match (matched-related donor).
For those individuals without a sibling match (70 percent of patients) the search is entered into a registry of donors through the National Marrow Donor Program, where a potential donor is identified (matched-unrelated donor). For those without a full match alternative donor transplants such as umbilical cord or haploidentical transplants (parent or children) may be considered.
The patient’s type of cancer, age, general health, availability of donors, and other factors determine whether an autologous or allogeneic transplant is performed.
The Cancer Transplant Institute at the Virginia G. Piper Cancer Center at HonorHealth has been recognized by the NMDP. It is also one of only 106 U.S. bone marrow transplant centers accredited by the Foundation for the Accreditation of Cellular Therapy for both autologous and allogeneic transplants.
Veena Fauble, MD, is a physician at the Cancer Transplant Institute at the Virginia G. Piper Cancer Center at HonorHealth. For more information about bone marrow transplants available at HonorHealth, please contact an oncology nurse navigator at 480-323-1339 or HonorHealth/cancer.
Recently, the nursing staff at the infusatorium, where I receive treatment, took it upon themselves to start a cancer support group. The monthly meetings are open to all cancer patients […]
I have just been awoken from my sleep, and as I begin to type this in the bright lights of my bedroom, it’s 04:50hrs. I am awake not because I need to urinate, despite that being the most common reason for my sleep being interrupted. I was forced out of my sleep tonight because my […]
Just over four weeks ago, on a Wednesday evening, I sat on my sofa brimming with excitement. I really do mean brimming. My cup was running well and truly over. There was so much excitement in my belly that I felt almost giddy. In me, giddiness general manifests in mumbling to myself and occasionally rubbing […]
After stem cell transplants for blood cancers, patients — with help from their caregivers — must be careful to avoid infections.
Nikki Mann knows first-hand that it takes patience, diligence and teamwork to help a loved one recover from a stem-cell transplant following a blood cancer diagnosis.
Her husband, Bill Mann, successfully underwent a stem-cell transplant in 2004, four years after he was diagnosed with multiple myeloma at the age of 45.
Although the transplant was uncharted territory for the Manns, Nikki’s role as caregiver had already been cemented through their initial years of his cancer saga. This time, they both had to be mindful of the heightened risk for infection in the ensuing days and weeks, because a stem-cell recipient’s immune system is weakened for a period of time after a transplant.
From an infection standpoint, the main risks are viral and fungal infections, but some bacterial infection risk is present too, particularly for patients whose treatment regimen relies on intravenous catheters that stay implanted for months at a time, says medical oncologist Ravi Vij, a specialist in bone marrow/stem cell transplants at the Siteman Cancer Center at the Washington University School of Medicine in St. Louis, Mo.
Since my cord blood transplant I have been beset by one viral infection after another and sometimes two at the same time. Apparently it is more common with cord blood transplants because the stem cells are immunologically naive, more so … Continue reading →
I started this post over a month ago but have never been well enough to finish it before something else happens that I want to write about so I am continually playing catch up or editing the post. Rather than … Continue reading →